- UroToday Home
- Recent Abstracts
- Urologic Oncology
Renal Cancer
Exploration of Prognostic Immune-Related Genes and lncRNAs Biomarkers in Kidney Renal Clear Cell Carcinoma and Its Crosstalk with Acute Kidney Injury.
February 24, 2022
Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma.
February 23, 2022
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.
February 23, 2022
Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma.
February 22, 2022
The prognostic impact of Claudin 6 in papillary renal cell carcinoma.
February 21, 2022
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
February 21, 2022
Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
February 21, 2022
Renal Cell Carcinoma Surgical Treatment Disparities in American Indian/Alaska Natives and Hispanic Americans in Arizona.
February 17, 2022
The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics-Definition, Current Advances, and Future Directions.
February 17, 2022
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?
February 17, 2022
Systematic Review With Meta-Analysis: Diagnostic, Prognostic and Clinicopathological Significance of CircRNA Expression in Renal Cancer.
February 16, 2022
Perspectives on the Role of Biopsy for Management of T1 Renal Masses: Survey Results from Two Regional Quality Improvement Collaboratives.
February 15, 2022
Partial vs. radical nephrectomy in non-metastatic pT3a kidney cancer patients: a population-based study.
February 15, 2022
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point.
February 14, 2022